title: Assessment of and physician response to glycemic control in diabetic patients presenting with an acute coronary syndrome.
abstract: BACKGROUND
  Diabetes mellitus (DM) is a common comorbidity among patients with acute coronary syndrome (ACS). The frequency with which physicians assess diabetic patients' glycemic control during an ACS hospitalization is not known and may represent an opportunity for quality improvement.
  
  
  METHODS
  This study describes the proportion of diabetic patients who had an assessment of their glycemic control (HbA1c) at the time of an ACS hospitalization. Secondary analyses examined characteristics associated with HbA1c assessment and physicians' responses to poor glycemic control.
  
  
  RESULTS
  Among 968 enrolled patients with ACS, 235 (24%) had DM. HbA1c values were known or obtained in 162 (69%) patients; 60% were poorly controlled (HbA1c > 7). Older patients were less likely to have an HbA1c assessment (relative risk [RR] = 0.81 [95% CI 0.64-1.01] for patients 60-69 years and RR = 0.71 [95% CI 0.58-0.88] for those > or = 70 years compared to patients < 60 years, P = .004). Among patients without an HbA1c, only consultation by an endocrinologist was independently associated with obtaining a subsequent assessment (RR 1.60, 95% CI 1.33-1.92, P < .001). Among those with an elevated HbA1c, 42% with an HbA1c of 7 to 9 and 69% of those with HbA1c > 9 had their diabetic regimen increased.
  
  
  CONCLUSIONS
  Almost one third of diabetic patients with ACS do not have HbA1c assessment at discharge; particularly older patients and those not evaluated by an endocrinologist. Although > 60% of those assessed had poor control, many did not have adjustments of their diabetic therapy. Assessment of diabetes represents an opportunity to improve the quality of care for diabetic patients with ACS.
authors.affiliation: Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO 64111, USA. conawayd@umkc.edu
authors.forename: Darcy L
authors.initials: DL
authors.lastname: Green Conaway
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Enriquez
authors.forename: Jaime E
authors.initials: JE
authors.lastname: Barberena
authors.forename: Philip G
authors.initials: PG
authors.lastname: Jones
authors.forename: James H
authors.initials: JH
authors.lastname: O'Keefe
authors.forename: John A
authors.initials: JA
authors.lastname: Spertus
mesh_terms: D000208:Acute Disease; D017677:Age Distribution; D000368:Aged; D003327:Coronary Disease / Q000097:blood* / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000097:blood* / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006403:Hematologic Tests / Q000706:statistics & numerical data; D006760:Hospitalization; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010351:Patient Discharge / Q000706:statistics & numerical data; D011785:Quality Assurance, Health Care; D013577:Syndrome
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents